EQS-News: PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million
October 2023 - The Management Board of the specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) has today decided, with the approval of the Supervisory Board, to increase the share capital of the company by partially utilizing the authorized capital by way of a rights issue with target gross proceeds of EUR 10 million.
- October 2023 - The Management Board of the specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) has today decided, with the approval of the Supervisory Board, to increase the share capital of the company by partially utilizing the authorized capital by way of a rights issue with target gross proceeds of EUR 10 million.
- PAION AG will publish the securities prospectus on its website (www.paion.com) after its approval by BaFin.
- Tilmann Bur, CEO of PAION AG, commented: "This capital increase lays the foundation for future growth and a successful market entry of Byfavo® in general anesthesia in Europe.
- We are particularly encouraged by the commitment of Humanwell and Nice & Green to participate in this capital increase.